The clinical performance is complex and often involves multi-systematic fatigue. Early identification and standardized diagnosis are critical to improving prognosis. The diagnosis of the disease requires a combination of clinical performance, imaging inspection, laboratory testing and pathological activation.
The platform can assist in matching teams of domestic and foreign authoritative experts to provide accurate diagnostics and treatment programs. Treatment and management of the treatment of the PF-ILD requires individual development, typically including pharmacotherapy, rehabilitation interventions, regular follow-up, and multidimensional management. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, many previously difficult-to-treat infectious respiratory digestive endocrine disorders have been significantly improved.
Therapeutic efficacy and adverse reactions need to be closely monitored and timely adjusted according to changes in the course of treatment. Multidisciplinary collaboration (MDT) is particularly important for the integrated management of the PF-ILD companion fluid. 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.